Bone turnover markers in the management of postmenopausal osteoporosis

被引:161
作者
Brown, Jacques P. [1 ]
Albert, Caroline [2 ]
Nassar, Bassam A. [3 ]
Adachi, Jonathan D. [4 ]
Cole, David [5 ]
Davison, K. Shawn [1 ]
Dooley, Kent C. [6 ]
Don-Wauchope, Andrew [4 ]
Douville, Pierre [1 ]
Hanley, David A. [7 ]
Jamal, Sophie A. [5 ]
Josse, Robert [5 ]
Kaiser, Stephanie [3 ]
Krahn, John [8 ]
Krause, Richard [7 ,9 ]
Kremer, Richard [10 ]
Lepage, Raymond [11 ]
Letendre, Elaine [2 ]
Morin, Suzanne [10 ]
Ooi, Daylily S. [12 ]
Papaioaonnou, Alexandra [4 ]
Ste-Marie, Louis-Georges [2 ]
机构
[1] Univ Laval, Quebec City, PQ, Canada
[2] Univ Montreal, Montreal, PQ, Canada
[3] Dalhousie Univ, Halifax, NS, Canada
[4] McMaster Univ, Hamilton, ON, Canada
[5] Univ Toronto, Toronto, ON, Canada
[6] LifeLabs Victoria Reg Lab, Victoria, BC, Canada
[7] Univ Calgary, Calgary, AB, Canada
[8] Univ Saskatchewan, Saskatoon, SK, Canada
[9] Calgary Lab Serv, Calgary, AB, Canada
[10] McGill Univ, Montreal, PQ, Canada
[11] Lab Med Biron, Brossard, PQ, Canada
[12] Univ Ottawa, Ottawa, ON, Canada
关键词
Biochemical markers; Bone turnover; Osteoporosis; Monitoring; Fracture; Biological variability; Recommendations; VERTEBRAL FRACTURE RISK; HEALTHY PREMENOPAUSAL WOMEN; COLLAGEN C-TELOPEPTIDES; LINKED N-TELOPEPTIDES; AUTOMATED SERUM ASSAY; BIOCHEMICAL MARKERS; I COLLAGEN; MINERAL DENSITY; BIOLOGICAL VARIABILITY; DEGRADATION-PRODUCTS;
D O I
10.1016/j.clinbiochem.2009.04.001
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
Osteoporosis is the most common cause of fragility fractures. Bone remodelling is essential for repairing damaged areas within bone to preserve bone strength and for assisting in mineral homeostases. In young adults, bone remodelling is Usually balanced with approximately as much bone replaced as is removed during each remodelling cycle. However, when remodelling becomes accelerated in combination with an imbalance that favours bone resorption over formation, such as during menopause, precipitous losses in bone mass occur. Bone turnover markers (BTMs) measure the rate of bone remodelling allowing for a dynamic assessment of skeletal status and hold promise in identifying those at highest risk of rapid bone loss and subsequent fracture. Further, the use of BTMs to monitor individuals administered osteoporosis therapy is attractive as monitoring anti-fracture efficacy with bone mineral density has significant limitations. This review details remodelling biology, pre-analytical and analytical sources of variability for BTMs, describes the most commonly used resorption and formation markers, and offers some guidelines for their use and interpretation in the laboratory and the clinic. (c) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:929 / 942
页数:14
相关论文
共 136 条
[1]
Determinants of bone turnover markers in healthy premenopausal women [J].
Adami, Silvano ;
Bianchi, Gerolamo ;
Brandi, Maria Luisa ;
Giannini, Sandro ;
Ortolani, Sergio ;
DiMunno, Ombretta ;
Frediani, Bruno ;
Rossini, Maurizio .
CALCIFIED TISSUE INTERNATIONAL, 2008, 82 (05) :341-347
[2]
Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[3]
Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis [J].
Bauer, DC ;
Garnero, P ;
Bilezikian, JP ;
Greenspan, SL ;
Ensrud, KE ;
Rosen, CJ ;
Palermo, L ;
Black, DM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (04) :1370-1375
[4]
Identification of peptide fragments generated by digestion of bovine and human osteocalcin with the lysosomal proteinases cathepsin B, D, L, H, and S [J].
Baumgrass, R ;
Williamson, MK ;
Price, PA .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (03) :447-455
[5]
*BECKM COULT INC, OST PROD INF
[6]
Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club [J].
Bergmann, P. ;
Body, J. -J. ;
Boonen, S. ;
Boutsen, Y. ;
Devogelaer, J. -P. ;
Goemaere, S. ;
Kaufman, J. -M. ;
Reginster, J. -Y. ;
Gangji, V. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (01) :19-26
[7]
Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis [J].
Bjarnason, NH ;
Sarkar, S ;
Duong, T ;
Mitlak, B ;
Delmas, PD ;
Christiansen, C .
OSTEOPOROSIS INTERNATIONAL, 2001, 12 (11) :922-930
[8]
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis [J].
Black, DM ;
Greenspan, SL ;
Ensrud, KE ;
Palermo, L ;
McGowan, JA ;
Lang, TF ;
Garnero, P ;
Bouxsein, ML ;
Bilezikian, JP ;
Rosen, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (13) :1207-1215
[9]
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women [J].
Blouin, Julie ;
Dragomir, Alice ;
Moride, Yola ;
Ste-Marie, Louis-Georges ;
Fernandes, Julio Cesar ;
Perreault, Sylvie .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (01) :117-127
[10]
Discontinuation of antiresorptive therapies: A comparison between 1998-2001 and 2002-2004 among osteoporotic women [J].
Blouin, Julie ;
Dragomir, Alice ;
Ste-Marie, Louis-Georges ;
Fernandes, Julio Cesar ;
Perreault, Sylvie .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (03) :887-894